No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
LXRX241220C1500
- 0.03
- 0.000.00%
15min DelayClose Dec 20 16:00 ET
0.00High0.00Low
0.00Open0.03Pre Close0 Volume360 Open Interest1.50Strike Price0.00Turnover0.00%IV96.91%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier-13DDays to Expiry0.03Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma25.90Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Express News | Lexicon Appoints Scott Coiante as Chief Financial Officer
Press Release: Lexicon Appoints Scott Coiante as Chief Financial Officer
Private Equity Firms Account for 47% of Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Ownership, While Institutions Account for 33%
Analysts Offer Insights on Healthcare Companies: Lexicon Pharmaceuticals (LXRX), Arcutis Biotherapeutics (ARQT) and Viking Therapeutics (VKTX)
Top Premarket Decliners
Needham Maintains Lexicon Pharmaceuticals(LXRX.US) With Hold Rating